Retrospective, monocentric observational study of pregnant women with an increased vascular risk and a primary prophylactic anticoagulation with certoparin in an intermediate dose of 8000iU sc od.

Retrospective, monocentric observational study of pregnant women with an increased vascular risk and a primary prophylactic anticoagulation with certoparin in an intermediate dose of 8000iU sc od. - PACER-VARP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00018099

Enrollment

Registered

2019-09-04

Start date

2019-09-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I80 O15

Interventions

Group 1: Retrospective, single-arm register study

sequential inclusion of probands from 2005 to date

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Pregnancy with moderate or high vascular risk; consent to off-label use of Certoparin

Exclusion criteria

Exclusion criteria: Pregnancy with low or very high vascular risk; contraindication to the administration of Certoparin

Design outcomes

Primary

Measure	Time frame
Efficacy of primary prophylactic anticoagulation with certoparin at a weight-independent dose of 8000 iE once daily; vascular endpoints such as thromboembolism and eclampsia are assessed	—

Secondary

Measure	Time frame
Safety of primary prophylactic anticoagulation with certoparin in a weight-independent dose of 8000 iE once daily; the rate of bleeding complications, skeletal complications and birth complications as well as the newborn's status (height, weight, limitations) are measured.	—

Countries

Germany

Contacts

Public ContactMartin Grünewald

Klinikum Heidenheim Medizinische Klinik I

martin.gruenewald@kliniken-heidenheim.de07321-332655

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026